Monday 8 June 2015, 14.00‐17.00

Lecture Theatre G34, Sir Alexander Fleming Building

This event gave Imperial staff and students an opportunity to hear about the College's partnership with the Francis Crick Institute from two of the Crick's directors

David Roblin, COO and Director of Scientific Translation, will talk about Discovery without Boundaries at the Crick.

Jim Smith, Director of Research, will focus on the Crick PhD programme and University secondments, sabbaticals and satellite groups at the Crick.

Watch the video of the event below or download the Crick Briefing Slides (pdf)‌.


Dr David Roblin, Crick COO and Director of Scientific Translation

David Roblin joined the Crick in September 2014. As well as taking on the role of COO, David also leads translational activities for the Crick as it accelerates its science for health and wealth benefits.

David practised medicine for five years before entering the pharmaceutical industry. He has held significant leadership roles in his pharmaceutical career, with general management, research, development and commercial responsibilities. He was formerly Senior Vice President, Head of Research, for Pfizer's European research and development. Since he left Pfizer in early 2011, David has been Chief Medical Officer and a Non-Executive Director to a number of biotech companies. He also serves on the Major Awards Committee of the Biomedical Catalyst Fund.

David has a degree in biochemistry from University College London and later qualified in medicine from St George's Hospital. He is a Fellow of the Royal College of Physicians, a member of the Faculty of Pharmaceutical Medicine and an honorary Professor of Medicine at Swansea University and Translational Medicine at St George's.

Dr Jim Smith: Crick Director of Research

Jim Smith is a Director of Research and group leader at the Francis Crick Institute, and he also serves as Deputy CEO and Chief of Strategy at the Medical Research Council.

Jim’s first degree was obtained from the University of Cambridge, and he was awarded his PhD at the Middlesex Hospital Medical School in 1979. After two years at Harvard Medical School studying growth factors and the cell cycle, he returned to the UK to work at the Imperial Cancer Research Fund on early amphibian development.

Jim became a group leader at the MRC National Institute for Medical Research (NIMR) in 1984. He moved to become Director of the Wellcome Trust/Cancer Research UK Gurdon Institute in Cambridge in 2000, and then returned to NIMR as Director in 2009.

He is a Fellow of the Royal Society and of the Academy of Medical Sciences.